OS Therapies Incorporated

OSTX • Biotechnology

$1.88

▲ +0.06 (+3.30%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$82.54M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez débil · 0.03Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 19 ago 2026, 12:14 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.88

Change3.30%

Shares Out43.90M

Market Cap$82.54M

Enterprise Value$-122.50M

52W Range1.15 - 2.57

Beta-0.73

P/E-0.01

P/B0.08

P/FCF-9.78

EV/EBITDA0.01

EV/FCF14.52

Price$1.88

Change3.30%

Shares Out43.90M

Market Cap$82.54M

Enterprise Value$-122.50M

52W Range1.15 - 2.57

Beta-0.73

P/E-0.01

P/B0.08

P/FCF-9.78

EV/EBITDA0.01

EV/FCF14.52

FCF Yield-10.22%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio0.03

Quick Ratio0.03

Volume225.03K

Avg Volume682.35K

EPS Surprise-0.10

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

20/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

89/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez débil · 0.03Rentabilidad débil

Analyst view

Analyst sentiment and price target

OSTX

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 8/1/2024

Industria: Biotechnology

P/B i: 0.08

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje4 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 0.03

Ratio rápido: 0.03

Estado: HighRisk

Advertencias

Weak Liquidity
Weak quick ratio

Transacciones internas

Actividad reciente de ejecutivos e insiders

EAGLE CRAIG

Transacción: 07/01/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/23/2026

Tipo

OTRO

Romness Paul A.

Transacción: 12/05/2024

COMPRA

Cambio

+500,000

Precio

$1.86

Presentación

05/15/2026

Tipo

COMPRA

Galzahr Karim

Transacción: 01/22/2026

COMPRA

Cambio

+50,000

Precio

$1.34

Presentación

02/13/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
EAGLE CRAIG	OTRO	0	Not reported	07/01/2026	07/23/2026
Romness Paul A.	COMPRA	+500,000	$1.86	12/05/2024	05/15/2026
Galzahr Karim	COMPRA	+50,000	$1.34	01/22/2026	02/13/2026
Jarry Olivier Roger	COMPRA	+50,000	$1.34	01/22/2026	02/13/2026
Romness Paul A.	COMPRA	+1,000,000	$1.34	01/22/2026	02/13/2026
PETIT ROBERT	COMPRA	+100,000	$1.34	01/22/2026	02/13/2026
Acevedo Christopher P.	COMPRA	+100,000	$1.34	01/22/2026	02/13/2026
Ciccio John	COMPRA	+50,000	$1.34	01/22/2026	02/13/2026
Search Theodore F.	COMPRA	+50,000	$1.34	01/22/2026	02/13/2026
McKean-Dieser Avril Suzette	COMPRA	+50,000	$1.34	01/22/2026	02/13/2026
Romness Paul A.	COMPRA	+1,000,000	$1.80	10/21/2025	02/13/2026
McKean-Dieser Avril Suzette	COMPRA	+140,000	$1.80	10/21/2025	12/19/2025
Acevedo Christopher P.	COMPRA	+200,000	$1.80	10/21/2025	12/19/2025
Ciccio John	COMPRA	+140,000	$1.80	10/21/2025	12/19/2025
Galzahr Karim	COMPRA	+140,000	$1.80	10/21/2025	12/19/2025
Jarry Olivier Roger	COMPRA	+140,000	$1.80	10/21/2025	12/19/2025
Romness Paul A.	COMPRA	+1,950,000	$1.80	10/21/2025	12/19/2025
PETIT ROBERT	COMPRA	+500,000	$1.80	10/21/2025	12/19/2025
Search Theodore F.	COMPRA	+140,000	$1.80	10/21/2025	12/19/2025
Auerbach Shalom	OTRO	0	Not reported	05/09/2025	05/09/2025

Sobre la compañía

OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Fuente - Link

Competidores

ADAG COEP CRVO EQ HOWL INKT IOBT NRXP OTLK SPRB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in September 2026 RMAT and Rolling Review decisions expected to follow U.S. FDA meeting Final 3-year overall survival data, U.S. FDA Pre-BLA Meeting, BLA submission, MHRA CMAA submission, and EMA CMAA submission expected in Q4 2026 Confirmatory Phase 3 Clinical Trial Application to follow MHRA meeting for Q4 2026 trial commencement OS Animal Health to attend Moody Capital Disruptive Growth & Life Sciences Conference New York and Rockville, Maryland--(Newsfile Corp. - September 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its management team, its business development advisors and the management team of its wholly-owned subsidiary OS Animal Health will participate in upcoming conferences, and provided a program update for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"): Jefferies Global Healthcare Conference: London - November 16-19, 2026 H.C.

Newsfile Corp

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program Interim 3-year Overall Survival data expected in early September 2026 ahead of MHRA Statistical Methods Scientific Advice Meeting for Conditional MAA submission acceptance criteria Final 3-year Overall Survival data to be included in FDA BLA Accelerated Approval Program submission ahead of Type B Pre-BLA Meeting previously granted in Q2/26 U.K. waives Pediatric Investigation Plan (PIP) requirement New York and Rockville, Maryland--(Newsfile Corp. - August 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today reported financial results for the second fiscal quarter ended June 30, 2026, and provided business and regulatory updates. The Company is seeking to obtain a Biologics License Application (BLA) under the Accelerated Approval Program of the U.S. Food & Drug Administration (FDA), and equivalent Conditional Marketing Accelerated Authorisations (CMAAs) from the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA), for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program").

Newsfile Corp

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival benefit observed between 2-year and 2.5-year timepoints U.K. MHRA Statistical Methods Scientific Advice Meeting granted in parallel New York, New York and Rockville, Maryland--(Newsfile Corp. - August 13, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's requested Type C Statistical Methods meeting to review the 2.5 year overall survival data from the Phase 2b trial of OST-HER2 in the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Trial"). The Company expects the FDA Type C Statistical Methods Meeting to occur in mid-September 2026 with members from division within the Center for Biologics Evaluation and Research (CBER), in parallel with the pending Biomarker Data Review Meeting being scheduled with members of the Center for Drug Evaluation and Research's (CDER) Biomarker Qualification Program (BQP).

Newsfile Corp

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods Meeting New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to review the Company's pharmacodynamic response biomarker data (the "OST-HER2 Biomarker Data") – patent pending. CDER's Biomarkers, EndpointS, and other Tools (BEST) resources is part of its Biomarker Qualification Program (BQP).

Newsfile Corp

OS Therapies Third Quarter 2026 Corporate Outlook

Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on upcoming clinical and regulatory milestones for the Company's lead program OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"), advancements with the Company's animal health-focused subsidiary OS Animal Health, Inc. (OSAH) and the Company's financial position as key regulatory and corporate milestones come into focus.

Newsfile Corp

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-18	-0.17	-0.27	-0.1
2026-03-31	-0.136	-0.35	-0.214
2025-11-14	-0.16	-0.21	-0.05
2025-08-19	-0.15	-0.19	-0.04
2025-05-15	-0.11	-0.18	-0.07
2025-03-31	-0.14	-0.24	-0.1
2024-11-15	-0.12	-0.18	-0.06
2024-08-14	-0.26	-0.26	0